UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):

November 6th, 2019

 

CANNABICS PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

 

 

Nevada 333-192759 20-3373669
(State of incorporation) (Commission File Number) (IRS Employer No.)

 

 

#3 Bethesda Metro Center

Suite 700

Bethesda, Md 20814

(Address of principal executive offices and Zip Code)

 

877 424-2429

(Registrant's telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on
which registered
Common Stock, par value $0.0001 per share   CNBX   OTCQB

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company   ☐         

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

 

     
 

 

 

Item 4.01 Changes in Registrant's Certifying Accountant   

 

Cannabics Pharmaceuticals Inc. (the “Company”) has dismissed BDO Ziv Haft (“Former Accounting Firm”) as its independent registered public accounting firm, effective as of November 6th, 2019.  As described in Item 4.01(a) below, the change in independent registered public accounting firm is not the result of any disagreement with the Former Accounting Firm. The Board made the decision to dismiss the Former Accounting Firm acting under authority delegated to it and the Board of Directors approved the same on November 6th, 2019. On the same date, the Company engaged Weinstein International CPA, 17 Kissufim St, Jerusalem, Israel (“the new accounting firm”) as its new independent accounting firm as of and for the year ended August 31st, 2019.

 

During the years ended August 31, 2018 and 2017, and through the Dismissal Date, there were (i) no disagreements between the Company and BDO Ziv Haft on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreement, if not resolved to the satisfaction of BDO Ziv Haft, would have caused them to make reference thereto in their reports on the consolidated financial statements for such years, and (ii) no “reportable events” as that term is defined in Item 304(a)(1)(v) of Regulation S-K.

 

The Company has not consulted with the New Accounting Firm during our two most recent fiscal years or during any subsequent interim period prior to its appointment as New Accounting Firm regarding either (i) the application of accounting principles to a specified transaction, either completed or proposed; or the type of audit opinion that might be rendered on our financial statements, and neither a written report was provided to us nor oral advice was provided that the New Accounting Firm concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject of disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a reportable event (within the meaning of Item 304(a)(1)(v) of Regulation S-K).

 

The Company has requested that the Former Accounting Firm furnish it with a letter addressed to the Securities and Exchange Commission stating whether or not it agrees with the above statement. A copy of the letter from the Former Accounting Firm is attached hereto as Exhibit 16.1 to this Form 8-K

 

Item 9.01 Financial Statements & Exhibits

 

(d) Exhibits

  3.1    Board Resolution

16.1    Letter from BDO Ziv Haft

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

  Cannabics Pharmaceuticals Inc.
   
  By:  /s/ Eyal Barad
    Eyal Barad
Director, CEO

Date: November 7, 2019

Cannibics Pharmaceuticals (QB) (USOTC:CNBX)
Historical Stock Chart
From Aug 2020 to Sep 2020 Click Here for more Cannibics Pharmaceuticals (QB) Charts.
Cannibics Pharmaceuticals (QB) (USOTC:CNBX)
Historical Stock Chart
From Sep 2019 to Sep 2020 Click Here for more Cannibics Pharmaceuticals (QB) Charts.